Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Favor

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 13, 2017
Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycleGregory R Ott, David A Favor
Bioorganic & Medicinal Chemistry Letters|October 2, 2013
Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonistsAlan Brown, David Ellis, David A Favor, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychoticsDavid A Favor, James J Powers, Andrew D White, et al.
The Journal of Organic Chemistry|October 25, 2001
Azide and Cyanide Displacements via Hypervalent Silicate IntermediatesEric D. Soli, Amy S. Manoso, Michael C. Patterson, et al.
Journal of the American Chemical Society|November 14, 2008
Total synthesis of (+)-azaspiracid-1. An exhibition of the intricacies of complex molecule synthesisDavid A Evans, Lisbet Kvaernø, Travis B Dunn, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2011
Sulfonamides as selective oestrogen receptor β agonistsLee R Roberts, Duncan Armor, Carolyn Barker, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorderDouglas S Johnson, Chung Choi, Lorraine K Fay, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|August 13, 2017
Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycleGregory R Ott, David A Favor
Bioorganic & Medicinal Chemistry Letters|October 2, 2013
Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonistsAlan Brown, David Ellis, David A Favor, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychoticsDavid A Favor, James J Powers, Andrew D White, et al.
The Journal of Organic Chemistry|October 25, 2001
Azide and Cyanide Displacements via Hypervalent Silicate IntermediatesEric D. Soli, Amy S. Manoso, Michael C. Patterson, et al.
Journal of the American Chemical Society|November 14, 2008
Total synthesis of (+)-azaspiracid-1. An exhibition of the intricacies of complex molecule synthesisDavid A Evans, Lisbet Kvaernø, Travis B Dunn, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2011
Sulfonamides as selective oestrogen receptor β agonistsLee R Roberts, Duncan Armor, Carolyn Barker, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorderDouglas S Johnson, Chung Choi, Lorraine K Fay, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Pageof 1